Colorectal cancer
Conditions
Interventions
Treatment group:Raltitrexed 3 mg/m^2 + Oxaliplatin 130 mg/m^2 + Bevacizumab 7.5 mg/kg
Sponsors
Medical Oncology Fujian Medical University Union Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 75 years, male or female; 2. Histologically or cytologically confirmed colorectal adenocarcinoma; 3. Diagnosed as metastatic colorectal cancer for the first time and cannot undergo radical resection after evaluation, or relapsed more than 12 months after radical operation; 4. At least one measurable lesion (long diameter >= 10 mm or short diameter >= 15 mm for lymph nodes on spiral CT scan as required by RECIST v1.1); 5. Blood routine examination, liver and kidney function meet the following requirements within 7 days before filter: absolute neutrophil count >= 1.5x10^9/L; hemoglobin >= 90 g/L; platelets >= 75x10^9/L; serum total bilirubin = 6 months; 7. ECOG 0 ~ 2; 8. Voluntary informed consent.
Exclusion criteria
Exclusion criteria: 1. Other malignant tumor history, except cured cervical carcinoma in situ and skin basal carcinoma within 5 years; 2. Intestinal obstruction or incomplete intestinal obstruction (need surgical intervention) 3. Any of the following incidences occurred within 6 months before enrollment: cerebrovascular accident (including stroke or transient ischemic attack), myocardial infarction, severe/unstable angina, coronary artery/peripheral artery bypass, congestive heart failure NYHA grade III or IV, arrhythmia requiring medical treatment or clinical significance, prolonged QT interval of electrocardiogram, etc.; 4. Any of the following occurred within 3 months before enrollment: gastric or duodenal ulcer resistant to treatment, erosive esophagitis or gastritis, grade 3 or 4 gastrointestinal oozing/bleeding/hematochezia, gastrointestinal tract perforation/fistula, deep vein thrombosis and pulmonary embolism or other uncontrolled thromboembolic events; 5. Hypersensitivity to study regimen chemotherapy agents; 6. Known central nervous system and brain metastases; 7. According to the judgment of the investigator, those with concomitant diseases that seriously threat the safety of the patient or affect the completion of the study; 8. Pregnant or lactating women 9. Other conditions that investigator think should be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective Response Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progress Free Survival;Overall Survival;Disease Control Rate;Quality of Life;Adverse Event;Serious Adverse Event; | — |
Countries
China
Contacts
Public ContactLin Xiaoyan
Fujian Medical University Union Hospital
Outcome results
None listed